| Page 14 | Aplastic Anemia and MDS International Foundation

AMA on AHCA: New Changes Are Not Fixes

The most recent effort to broaden support for the American Health Care Act (AHCA), which comes in the form of an amendment proposed by New Jersey Rep. Tom MacArthur, does not address the most serious flaws in the bill and would also undermine critical health insurance consumer protections. For these reasons, the AMA “remains opposed to passage of this legislation,” the Association’s CEO and Executive Vice President, James L. Madara, MD, said today in a letter to House Republican and Democratic leaders.

FYI: AARP Calls Health Bill Hazardous

A bill slated for a vote in the U.S. House of Representatives this week threatens your health — and your wallet — in many ways. The American Health Care Act (AHCA) was pulled from consideration in March because it lacked the votes. House leaders say they are mustering support for a revised version of the AHCA despite opposition from doctors, hospitals and consumer groups, including AARP. They hope to have a vote on the bill this week. Among the key provisions, the legislation would:

A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients

Author(s): 
Mercuri A, Farruggia P, Timeus F, Lombardi L, Onofrillo D, Putti MC, Pillon M, Cantarini ME, Corti P, Tridello G, De Bortoli M, Pegoraro A, Cesaro S
Primary Author: 
Mercuri A
Journal Title: 
Blood Cells Mol Dis
Original Publication Date: 
Mar 2017

Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients

Author(s): 
Saeed L, Patnaik MM, Begna KH, Al-Kali A, Litzow MR, Hanson CA, Ketterling RP, Porrata LF, Pardanani A, Gangat N, Tefferi A
Primary Author: 
Saeed L
Journal Title: 
Blood Cancer J
Original Publication Date: 
Mar 2017

Current prognostic models for

Bone Marrow Diseases: 

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes

Author(s): 
Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G
Primary Author: 
Daher M
Journal Title: 
Am J Hematol
Original Publication Date: 
Mar 2017

Bone Marrow Diseases: 

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Author(s): 
Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME
Primary Author: 
Scott BL
Journal Title: 
J Clin Oncol
Original Publication Date: 
Apr 2017

Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with reduced-intensity conditioning (RIC) would result in improved overall survival (OS) compared with myeloablative conditioning (MAC).

Bone Marrow Diseases: 

2017 March for Marrow: Miami

Get up, get out and get going! The walk will proceed along the scenic path. Festivities include a Moment of Remembrance, light refreshments, inspirational speakers, and a morning of fun connecting with fellow patients and families affected by a

Event Date: 
Sat, 06/03/2017 -
9:00am to 11:00am
Community Event Type: